Name (Synonyms) | Correlation | |
---|---|---|
D019896 | Alpha 1-Antitrypsin Deficiency NIH | 1.00 |
D004646 | Emphysema NIH | 0.71 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.35 |
D008173 | Lung Diseases, Obstructive NIH | 0.33 |
D008171 | Lung Diseases, NIH | 0.26 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006510 | Chronic pulmonary obstruction HPO | 0.35 |
HP:0006536 | Pulmonary obstruction HPO | 0.33 |
HP:0002088 | Abnormal lung morphology HPO | 0.26 |
There is one clinical trial.
Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
Description: mortality rates in two groups will be compared
Measure: mortality Time: 4 months